Provectus Pharmaceuticals Inc. is quickly gaining a reputation as an up-and-coming development-stage oncology and dermatology biopharmaceutical company. Helping to enhance this reputation and its position in the marketplace, Provectus announced the addition of Mount Sinai School of Medicine as the second and final site for its expanded Phase 2 clinical trial of the company’s lead dermatology agent PH-10 for psoriasis. Jason Elmer, M.D., who served as the lead investigator for the Phase 2 clinical trial of PH-10 for atopic dermatitis of which patent enrollment was completed in June, will also serve as the principal investigator of this trial.

Commenting on the value of Dr. Elmer’s work on this project, Provectus CEO Craig Dees, Ph.D. stated, “Dr. Emer’s work with PH-10 for atopic dermatitis, his involvement in the ongoing research of the product as a dermatological therapy, and Mount Sinai School of Medicine’s outstanding reputation in dermatological research make this

Stock-PR OTC Stock Report August 18, 2009

Insight Management Corporation (OTCBB: ISIM) President and CEO, Jennifer Rapacki, August 18, 2009 commented on positive trends in the domestic natural gas services market. “While existing natural gas wells continue to demand maintenance, new drilling activity should create added demands for service,” Ms. Rapacki noted. “We are now seeing an increase in leasing activity and are very encouraged about how that will translate into higher revenues for service companies like ours in the remainder of this year.”

Sector 10, Inc. (OTCBB:SECI) (Frankfurt:4SR) announced that it has submitted proposals to multiple cities regarding the deployment of the Pilot PLX-3D system. The proposals were sent in response to inquiries received from the announcement of the Pilot PLX-3D deployment program in the July 21, 2009 press release. The PLX-3D deployment and the related installation of SRU’s are designed to help communities better prepare for emergencies, disasters and

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

Tuesday August 18, 2009

PennyOmega.com Stock Report!

**************************************************************

Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, has added Mount Sinai School of Medicine as its second and final site for its expanded Phase 2 clinical trial of the Company’s lead dermatology agent PH-10 for psoriasis. Jason Emer, M.D. will serve as principal investigator of the trial; he is also the lead investigator for the Phase 2 clinical trial of PH-10 for atopic dermatitis, for which patient enrollment was completed in June.

Consistent with its ongoing efforts to enhance services offered to its customers and contract services clients, SouthWest Water Company (NASDAQ:SWWC), a leading provider of

Yesterday, Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, held its 2009 Annual Meeting of Shareholders in Knoxville, Tennessee. During the meeting, shareholders voted to re-elect the company’s five members of the Board of Directors, which is composed of three inside directors, and two outside directors. Each Director serves a one-year term.

Dr. Dees, CEO of Provectus commented, “We appreciate the confidence of our shareholders as Provectus continues to achieve its milestones for the development of PV-10 and PH-10. Our recently reported ASCO data support our mission to continue our quest to find a viable, safe and effective treatment for metastatic melanoma, and further our research towards that end. Having completed patient accrual in May for our phase 2 melanoma trial, we look forward to communicating additional results to the scientific community and investors in coming months.”

Dr. Dees continued, “While our primary focus has been directed towards